InsiderTrades.com logo

AIM Insider Trading

Insider Ownership Percentage: 0.04%
Insider Buying (Last 12 Months): $17,268.00
Insider Selling (Last 12 Months): $0.00

AIM ImmunoTech Insider Trading History Chart

This chart shows the insider buying and selling history at AIM ImmunoTech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AIM ImmunoTech Share Price & Price History

Current Price: $1.47
Price Change: ▲ Price Increase of +0.07 (5.00%)
As of 12/4/2025 05:10 PM ET

This chart shows the closing price history over time for AIM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

AIM ImmunoTech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/4/2025Peter W. Rodino, IIICOOBuy5$9.00$45.004,017View SEC Filing Icon  
4/4/2025Thomas K EquelsCEOBuy410$6.00$2,460.0018,990View SEC Filing Icon  
3/4/2025Thomas K EquelsCEOBuy833$12.00$9,996.0017,640View SEC Filing Icon  
12/18/2024Thomas K EquelsCEOBuy227$21.00$4,767.0016,806View SEC Filing Icon  
12/2/2024Stewart AppelrouthDirectorBuy111$21.00$2,331.003,555View SEC Filing Icon  
11/20/2024Stewart AppelrouthDirectorBuy819$19.00$15,561.003,217View SEC Filing Icon  
11/20/2024Thomas K EquelsCEOBuy601$18.00$10,818.0015,529View SEC Filing Icon  
9/16/2024Thomas K EquelsCEOBuy50$30.00$1,500.0014,930View SEC Filing Icon  
5/6/2024Peter W. Rodino, IIICOOBuy308$41.00$12,628.002,125View SEC Filing Icon  
5/6/2024Thomas K EquelsCEOBuy617$41.00$25,297.007,781View SEC Filing Icon  
3/21/2024Nancy BryanDirectorBuy384$39.00$14,976.00384View SEC Filing Icon  
3/15/2024Peter W. Rodino, IIICOOBuy378$33.00$12,474.001,817View SEC Filing Icon  
3/15/2024Stewart AppelrouthDirectorBuy909$33.00$29,997.002,397View SEC Filing Icon  
3/15/2024Thomas K EquelsCEOBuy757$33.00$24,981.007,164View SEC Filing Icon  
11/27/2023Thomas K EquelsCEOBuy338$44.00$14,872.006,406View SEC Filing Icon  
9/29/2023Thomas K EquelsCEOBuy226$44.00$9,944.006,068View SEC Filing Icon  
8/24/2023Thomas K EquelsCEOBuy149$67.00$9,983.005,759View SEC Filing Icon  
7/17/2023Thomas K EquelsCEOBuy169$59.00$9,971.005,609View SEC Filing Icon  
1/3/2023Stewart AppelrouthDirectorBuy806$31.00$24,986.002,170View SEC Filing Icon  
1/3/2023Thomas K EquelsCEOBuy1,612$31.00$49,972.005,439View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for AIM ImmunoTech (NYSEAMERICAN:AIM)

12.02% of AIM ImmunoTech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AIM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

AIM ImmunoTech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/14/2025Sabby Management LLC28,855$79K0.1%N/A1.065%Search for SEC Filing on Google Icon
9/26/2025Corient Private Wealth LLC10,001$87K0.0%N/A0.369%Search for SEC Filing on Google Icon
8/15/2025Corient Private Wealth LLC10,001$87K0.0%N/A1.309%Search for SEC Filing on Google Icon
2/17/2025Citadel Advisors LLC358,987$71K0.0%-21.6%0.563%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC4,078,000$1.52M0.0%N/A7.919%Search for SEC Filing on Google Icon
11/16/2021Verition Fund Management LLC148,479$0.30M0.0%+37.5%0.310%Search for SEC Filing on Google Icon
11/15/2021HighTower Advisors LLC41,095$82K0.0%-38.8%0.086%Search for SEC Filing on Google Icon
10/28/2021WINTON GROUP Ltd82,564$0.17M0.0%+50.4%0.173%Search for SEC Filing on Google Icon
10/19/2021Arkadios Wealth Advisors21,597$43K0.0%N/A0.045%Search for SEC Filing on Google Icon
8/16/2021State Street Corp160,413$0.35M0.0%N/A0.335%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp87,226$0.19M0.0%+28.8%0.182%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
AIM ImmunoTech logo
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Read More on AIM ImmunoTech

Today's Range

Now: $1.47
Low: $1.41
High: $1.51

50 Day Range

MA: $2.07
Low: $1.30
High: $2.76

52 Week Range

Now: $1.47
Low: $1.26
High: $36.00

Volume

45,964 shs

Average Volume

59,631 shs

Market Capitalization

$4.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Who are the company insiders with the largest holdings of AIM ImmunoTech?

AIM ImmunoTech's top insider investors include:
  1. Thomas K Equels (CEO)
  2. Peter W Rodino III (COO)
  3. Stewart Appelrouth (Director)
  4. Nancy Bryan (Director)
Learn More about top insider investors at AIM ImmunoTech.

Who are the major institutional investors of AIM ImmunoTech?

AIM ImmunoTech's top institutional investors include:
  1. Sabby Management LLC — 1.06%
Learn More about top institutional investors of AIM ImmunoTech stock.

Which institutional investors are buying AIM ImmunoTech stock?

In the last quarter, AIM stock was purchased by institutional investors including:
  1. Sabby Management LLC
Within the last year, these company insiders have bought AIM ImmunoTech stock:
  1. Thomas K Equels (CEO)
  2. Peter W Rodino III (COO)
  3. Stewart Appelrouth (Director)
  4. Nancy Bryan (Director)
Learn More investors buying AIM ImmunoTech stock.